RxSight (RXST) Stock Forecast: StockMap's 2-Week Call

RXST stock forecast: StockMap's model makes no two-week call on RxSight after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 3 of 6 two-week windows on RXST since Aug 21; by chance, a call on the same dates was right 58% of the time.

RxSight last closed at $4.61, -7.98% on the session.

Against the IVW growth benchmark the position is -5.65% over the forecast window.

RxSight's market cap is $193.30M as of November 19, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 1 (too close to call).

Where RXST sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 33%.

45 daily calls for RXST so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks RxSight in the 27th percentile on return on equity, where 100 is best.

RxSight is classified under Health Care / Health Care Equipment & Supplies.

StockMap tracks RxSight as the 93rd largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.

On that composite RxSight ranks 27th of 141 in the group, against a group median of -0.18.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

RxSight (RXST) — StockMap 2-week forecast & tracked accuracy